Y. Furukawa et al., Interleukin-10 (IL-10) augments allograft arterial disease - Paradoxical effects of IL-10 in vivo, AM J PATH, 155(6), 1999, pp. 1929-1939
Citations number
59
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research Diagnosis & Treatment
Interleukin-10 (IL-10) is an anti-inflammatory helper T cell type 2 (Th2) c
ytokine that modulates Th1-type cytokine production. Graft arterial disease
(GAD) is a vascular obliterative process mediated via the Th1 cytokine int
erferon-gamma (IFN-gamma); allografts in IFN-gamma-deficient animals do not
develop GAD, We investigated the effect of IL-10 and anti-IL-10 on GAD in
murine heart transplants and whether anti-IL-10 reestablishes GAD in IFN-ga
mma-deficient hosts. Major histocompatibility complex class II-mismatched h
earts were transplanted for 8 weeks into wild-type or IFN-gamma-deficient m
ice. In one set of experiments, wild-type hosts received daily administrati
on of phosphate-buffered saline (PBS) or increasing IL-10; in a subsequent
set of experiments, wild-type hosts received weekly PBS, rat IgG, or anti-I
L-10 monoclonal antibody; IFN-gamma-deficient recipients received weekly PB
S or anti-IL-10 monoclonal antibody. Explanted allografts were assessed for
parenchymal rejection and GAD, cytokine profiles, and adhesion/costimulato
ry-molecule expression. Exogenous IL-10 resulted in increased Th2-like cyto
kine production; nevertheless, it exacerbated parenchymal rejection and GAD
and increased CD8(+) infiltration. Anti-IL-10 did not significantly affect
the extent of rejection or GAD, cytokine profiles, or immunohistology of t
he allografts in wild-type hosts. Adhesion molecule (CD54 and CD106) expres
sion was not diminished by IL-10 treatment, and costimulatory-molecule (CD8
0 and CD86) expression was augmented by administration of exogenous IL-10.
Allografts in IFN-gamma-deficient recipients showed mild refection and no G
AD, regardless of anti-IL-10 treatment. IL-10 in vivo thus has markedly dif
ferent effects than predicted from in vitro experience. Although allografts
develop Th2-like cytokine profiles treatment with IL-10 causes exacerbated
rejection and GAD.